Using the CODEEVOLVER® directed evolution platform to create improved enzymes for molecular diagnostics by Mitchell, Vesna et al.
USING THE CODEEVOLVER® DIRECTED EVOLUTION PLATFORM TO CREATE IMPROVED ENZYMES 
FOR MOLECULAR DIAGNOSTICS 
 
Vesna Mitchell, Codexis, Inc., Redwood City CA, USA  
Vesna.Mitchell@codexis.com 
Matt Miller, Codexis, Inc., Redwood City CA, USA  
Sandy Gomes, Codexis, Inc., Redwood City CA, USA  
Nikki Dellas, Codexis, Inc., Redwood City CA, USA  
David Elgart, Codexis, Inc., Redwood City CA, USA 
Judy Viduya, Codexis, Inc., Redwood City CA, USA  
Jonathan Vroom, Codexis, Inc., Redwood City CA, USA 
 
 
Key words: molecular diagnostics, next generation sequencing, enzyme engineering 
 
Using advanced enzyme engineering technology, Codexis has developed practical, green manufacturing 
processes for a range of pharmaceutical intermediates and APIs, biologic drug discovery and food ingredients.  
Our enzyme engineering technology has produced a diverse array of enzymes that are operationally equivalent 
and complementary to the “standard” catalysts in the chemists’ tool box.  Parallel optimization of enzyme, enzyme 
formulation, and chemical process continues to push the catalyst cost contribution lower, expanding the 
application of custom-made enzymes into larger volume opportunities.   
 
Recently, Codexis announced that it will offer high-performance enzymes for customers using next generation 
sequencing (NGS) for in vitro molecular diagnostic applications.  Historically, NGS workflows relied on modestly 
engineered enzymes. As NGS is being pushed into new, more demanding applications, such as liquid biopsy 
and personalized medicine samples, more capable enzymes are required. Example of engineering an enzyme 
with improved analytical efficiency, processivity and fidelity while also reducing bias in preparation steps for 
NGS using the CodeEvolver directed evolution platform will be presented. 
